Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report issued on Thursday. The brokerage presently has a $1.25 target price on the biotechnology company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 9.65% from the stock’s previous close.

According to Zacks, “Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company’s product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. “

A number of other equities analysts also recently commented on BLPH. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Bellerophon Therapeutics in a report on Wednesday. ValuEngine downgraded shares of Bellerophon Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 10th.

Bellerophon Therapeutics (NASDAQ BLPH) traded down 0.87% during mid-day trading on Thursday, reaching $1.14. 267,420 shares of the company traded hands. Bellerophon Therapeutics has a 52-week low of $0.43 and a 52-week high of $1.98. The stock’s market capitalization is $40.48 million. The firm’s 50-day moving average is $1.22 and its 200 day moving average is $1.36.

Bellerophon Therapeutics (NASDAQ:BLPH) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. On average, equities research analysts expect that Bellerophon Therapeutics will post ($1.12) earnings per share for the current year.

WARNING: “Bellerophon Therapeutics, Inc. (BLPH) Upgraded to “Buy” by Zacks Investment Research” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States and international copyright laws. The original version of this piece can be accessed at

A number of institutional investors have recently added to or reduced their stakes in the business. Susquehanna International Group LLP bought a new stake in Bellerophon Therapeutics in the second quarter valued at $1,316,000. Renaissance Technologies LLC lifted its stake in Bellerophon Therapeutics by 99.7% in the first quarter. Renaissance Technologies LLC now owns 477,400 shares of the biotechnology company’s stock valued at $711,000 after buying an additional 238,300 shares during the last quarter. Vanguard Group Inc. lifted its stake in Bellerophon Therapeutics by 52.6% in the second quarter. Vanguard Group Inc. now owns 612,641 shares of the biotechnology company’s stock valued at $821,000 after buying an additional 211,111 shares during the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in Bellerophon Therapeutics in the first quarter valued at $125,000. 45.85% of the stock is owned by hedge funds and other institutional investors.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary diseases. The Company is focused on the development of its nitric oxide therapy for patients with pulmonary hypertension (PH), using its delivery system, INOpulse, with pulmonary arterial hypertension (PAH) as the lead indication.

Get a free copy of the Zacks research report on Bellerophon Therapeutics (BLPH)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Bellerophon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics Inc. and related companies with's FREE daily email newsletter.